Dr. Chuanhai Cao, Associate Professor of Pharmacy at the University of South Florida is a renowned Alzheimer’s researcher. He discovered that THC, the psychoactive cannabinoid found in the cannabis plant, in combination with other formulations, helps slow down the build-up of plaque in the brain that is a hallmark of Alzheimer’s disease. Hyalolex, which helps alleviate several end points of the disease, is based on Dr. Cao’s and other independent research.
We are a leader in cannabinoid-based combination therapy with a portfolio of seven patents filed with the United States Patent and Trademark Office (“USPTO”), for indications of Alzheimer’s, Parkinson’s, pain, seizures, and eating disorders. Our most advanced formulation for indications of Alzheimer’s will be available to patients in early 2018.
Our team has a unique and proven track record of successfully developing and bringing products to market, successfully navigating highly regulated industries, and creating large rapidly growing companies that have created enormous shareholder value.
Company is listed on the NYSE American: IGC
It is also available for trading on the Borse Frankfurt, Borse Berlin and Borse Stuttgart: IGS1
Yahoo Finance: IGC, IGS1.F, IGS1.BE, IGS1.SG
For FAQ visit our Investor Center.
Please provide us with your feedback. Or for queries, please contact us.